293 related articles for article (PubMed ID: 33835317)
1. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
2. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
3. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
[TBL] [Abstract][Full Text] [Related]
4. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
5. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
[TBL] [Abstract][Full Text] [Related]
6. In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV.
K PD; D RD; S B; B Narayanan VH
Sci Rep; 2022 Aug; 12(1):13907. PubMed ID: 35974065
[TBL] [Abstract][Full Text] [Related]
7. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
12. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier.
Khan AW; Kotta S; Ansari SH; Sharma RK; Ali J
Drug Dev Ind Pharm; 2015 May; 41(5):772-9. PubMed ID: 24669978
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
Jacobs TG; van Aerde KJ; Colbers A; Burger DM
Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
15. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
[TBL] [Abstract][Full Text] [Related]
17. Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of Dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions.
Lakshman D; Chegireddy M; Hanegave GK; Sree KN; Kumar N; Lewis SA; Dengale SJ
Eur J Pharm Sci; 2020 Jan; 142():105137. PubMed ID: 31706016
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
[TBL] [Abstract][Full Text] [Related]
19. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
Enoki Y; Kishi N; Sakamoto K; Uchiyama E; Hayashi Y; Suzuki N; Ito M; Taguchi K; Yokoyama Y; Kizu J; Matsumoto K
Drug Metab Pharmacokinet; 2021 Apr; 37():100371. PubMed ID: 33556698
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
Ciccullo A; Baldin G; Borghetti A; Di Giambenedetto S
Expert Rev Anti Infect Ther; 2020 Apr; 18(4):279-292. PubMed ID: 32067525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
